12:00 AM
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Linaclotide: Phase III started

Ironwood and Forest began a double-blind, placebo-controlled, North American Phase III trial to evaluate 150 and 300 µg oral linaclotide once daily for 26 weeks in 750 patients. Ironwood and Forest are co-developing...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >